Navigation Links
Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
Date:5/30/2008

Summary: Genmab has Initiated a Phase I/II Study of Zalutumumab in Combination With Irinotecan Chemotherapy to Treat Refractory Colorectal

Cancer Patients

COPENHAGEN, Denmark, May 30 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has initiated a Phase I/II study of zalutumumab (HuMax-EGFr(TM)) in combination with irinotecan chemotherapy to treat colorectal cancer (CRC). The study will include a maximum of 97 patients who have failed standard chemotherapy and progressed during or within three months of stopping cetuximab-based therapy.

"We are glad to expand the zalutumumab program with this new indication," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About the trial This open label study consists of two parts. In both parts of the study, patients will receive weekly doses until disease progression. Part 1 will include 3 to 15 patients who will receive weekly doses of first 8mg/kg of zalutumumab in combination with bi-weekly irinotecan and if safe patients will subsequently receive 16 mg/kg zalutumumab in combination with irinotecan.

Part 2 will be an open label randomized parallel group enrolling 14 to 82 patients pending the number of treatment arms and early termination from part 1. Patients in part 2 will receive weekly doses of zalutumumab with or without bi-weekly irinotecan administration until disease progression. In total a maximum of 97 patients will be enrolled into the study.

Safety data from Part 1 of the trial will be evaluated by an independent data monitoring committee who will determine if it is safe to begin Part 2. The objective of the study is to evaluate the safety and efficacy of zalutumumab in combination with irinotecan. The primary endpoint of the study is adverse events.

About Colorectal Cancer

CRC is a public health problem in developed countries. Although potentially curable in early stages, a proportion of pa
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 29, 2014  Ten of the most highly-respected ... repair, regeneration, allograft reconstruction and research and development, ... gathered to discuss the future of cartilage regeneration ... Medicine symposium, Cartilage Regeneration: State of the ... Biosurgery, Minced Juvenile Allograft, and State of the ...
(Date:9/29/2014)... security, emerging diseases and biodiversity loss requires evolutionary ... Science Express that was co-authored by ... of Agriculture and Life Sciences. , For the ... has reviewed progress in addressing a broad set ... using approaches that consider evolutionary histories and the ...
(Date:9/29/2014)... According to the ... (Modifying Enzymes, DNA Polymerase, Acetylase, Methyltransferase, Instruments ... by Research Area (Developmental Biology, Oncology), by ... published by MarketsandMarkets, provides a detailed overview ... market trends, and strategies impacting the global ...
(Date:9/29/2014)... Sept. 29, 2014  Atlas Venture, an early stage ... technology innovation, today announced that Jason Rhodes , ... EPZM ), is joining the firm,s life sciences ... At Atlas, Rhodes will work closely with ... brings an accomplished record in company creation, deal making ...
Breaking Biology Technology:World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2
(Date:9/30/2014)... KONG , Sept. 30, 2014 Winners of ... Economist Events, Innovation Summit scheduled to take place at the JW ... the summit, the award winners will share their experiences and the ... who have made a proven innovation over the past decade, will ... the night before the summit. It will be the first ...
(Date:9/29/2014)... Washington, DC Monday, September 29: Between 1970 ... and fish around the globe dropped 52 percent, ... by World Wildlife Fund (WWF). This biodiversity loss ... increasing resource use of high-income countries. , In ... the report,s data point to other warning signs ...
(Date:9/29/2014)... of Texas at Arlington research team says recently identified ... their lab could open doors for homeland security and ... in the Oct. 1 issue of Optics Letters ... co-authors describe a new method to fabricate transparent nanoscintillators ... until a transparent ceramic is formed. A scintillator ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Half of global wildlife lost, says new WWF report 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... scientists have begun to harness DNA,s powerful molecular machinery ... natural ability of pairs of DNA molecules to assemble ... the California Institute of Technology,* could provide a means ... and drug delivery systems, from the bottom up. ...
... . Sperm have only one aim: to find ... emitting attractants. Calcium ions determine the beating pattern of the sperm ... the Max Planck Institute for the Physics of Complex Systems in ... centre in Bonn, an institute of the Max Planck Society, have ...
... British Columbia is arguably the most important fossil deposit ... Cambrian "Explosion," the rapid flowering of complex life from ... comprised of shells, teeth and bones, the Burgess Shale ... delicate structuresof animals belonging to Earth,s earliest complex ecosystems ...
Cached Biology News:The shape of things to come: NIST probes the promise of nanomanufacturing using DNA origami 2Sperm can count 2Mechanism for Burgess Shale-type preservation 2
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
... system is designed for multiple user laboratories ... for TLC applications. The MultiDoc-It is available ... enclosure provides a darkroom environment and protects ... Use image capture and enhancement , ...
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Request Info...
Biology Products: